P-63 FOLFIRINOX in borderline resectable pancreatic carcinoma
نویسندگان
چکیده
منابع مشابه
Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma
5-Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We evaluated our institutional experience with neoadjuvant FOLFIRINOX in borderline resectable pancreatic adenocarcinoma (BRPAC). The primary endpoints were completion of therapy to surgery and negative resection margin (R0)...
متن کاملBorderline resectable pancreatic cancer.
Rigorous criteria to define "borderline resectable" pancreatic cancer are required for appropriate patient accrual into clinical trials that examine the utility of chemotherapy and/or chemoradiation that will be delivered prior to pancreatic resection for exocrine cancer. At our institution, tumor abutment of less than or equal to 180 degrees (< or = 50% of the vessel circumference) of the supe...
متن کاملNeoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinically detected. As such, the delivery of early systemic therapy may be a rational alternative to a surgery-first approach, in an effort to p...
متن کاملNovel approaches to 'borderline resectable' pancreatic tumors.
In this issue of ONCOLOGY, Shah and colleagues, through their instructive case report, draw our attention to an important area—borderline resectable pancreatic cancer—that has historically not been a major focus of the literature.[1] The authors describe the case of a 40-year-old man with an adenocarcinoma of the pancreatic head with involvement of the superior mesenteric vein–portal vein (SMV-...
متن کاملManagement of borderline resectable pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5%. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80% o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2020
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2020.04.145